Cargando…
Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals
BACKGROUND & OBJECTIVES: During the COVID-19 pandemic it was important to assess the antibody profile in individuals vaccinated with Covaxin (BBV152) and Covishield (ChAdOx1 nCoV-19) with both 28 and 84 days gaps between two doses, those infected with SARS-CoV-2 and post-COVID-19-infected indivi...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807196/ https://www.ncbi.nlm.nih.gov/pubmed/36124500 http://dx.doi.org/10.4103/ijmr.ijmr_3330_21 |
_version_ | 1784862669222707200 |
---|---|
author | Patil, Rucha Shanbhag, Sharda Shankarkumar, Aruna Madkaikar, Manisha |
author_facet | Patil, Rucha Shanbhag, Sharda Shankarkumar, Aruna Madkaikar, Manisha |
author_sort | Patil, Rucha |
collection | PubMed |
description | BACKGROUND & OBJECTIVES: During the COVID-19 pandemic it was important to assess the antibody profile in individuals vaccinated with Covaxin (BBV152) and Covishield (ChAdOx1 nCoV-19) with both 28 and 84 days gaps between two doses, those infected with SARS-CoV-2 and post-COVID-19-infected individuals vaccinated with only one dose of either of the vaccines. The present study was aimed to assess these objectives. METHODS: Fifty real time reverse transcription–polymerase chain reaction (qRT-PCR)-confirmed COVID-19-infected individuals, along with 90 COVID-19-naïve (BBV152 and ChAdOx1 nCov-19)–vaccinated individuals, were included in the study. Individuals who received a single dose of either vaccine with a confirmed past diagnosis of SARS-CoV-2 infection (n=15) were also included. Blood samples were collected strictly between the 4(th) and 5(th) wk after development of symptoms for SARS-CoV-2 infected individuals and after the first/second vaccination dose. Antibody profile assessment was done using whole-virus, spike-receptor binding domain (RBD) and nucleocapsid-specific ELISA kits along with neutralizing antibody kit. RESULTS: There was an overall 97.7 per cent seropositivity rate in vaccinated individuals, and a strong correlation (R(2)=0.8, P<0.001) between neutralizing and spike-RBD antibodies. Among individuals who received two standard doses of ChAdOx1 nCoV-19 vaccine, the spike antibody levels developed were of higher titre with a longer prime boost interval than in those with shorter intervals (P<0.01). Individuals vaccinated with two doses as well as only one dose post-SARS-CoV-2 infection had high neutralizing and spike-specific antibodies. INTERPRETATION & CONCLUSIONS: High neutralizing and spike-specific antibodies were developed in individuals vaccinated only with one dose of either vaccine post-SARS-CoV-2 infection. With the main priority being vaccinating majority of the population in our country, single-dose administration to such individuals would be a sensible way to make the most of the limited supplies. Furthermore, neutralizing antibody levels observed in COVID-19-naïve vaccinees imply the need for booster vaccination. |
format | Online Article Text |
id | pubmed-9807196 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-98071962023-01-03 Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals Patil, Rucha Shanbhag, Sharda Shankarkumar, Aruna Madkaikar, Manisha Indian J Med Res Original Article BACKGROUND & OBJECTIVES: During the COVID-19 pandemic it was important to assess the antibody profile in individuals vaccinated with Covaxin (BBV152) and Covishield (ChAdOx1 nCoV-19) with both 28 and 84 days gaps between two doses, those infected with SARS-CoV-2 and post-COVID-19-infected individuals vaccinated with only one dose of either of the vaccines. The present study was aimed to assess these objectives. METHODS: Fifty real time reverse transcription–polymerase chain reaction (qRT-PCR)-confirmed COVID-19-infected individuals, along with 90 COVID-19-naïve (BBV152 and ChAdOx1 nCov-19)–vaccinated individuals, were included in the study. Individuals who received a single dose of either vaccine with a confirmed past diagnosis of SARS-CoV-2 infection (n=15) were also included. Blood samples were collected strictly between the 4(th) and 5(th) wk after development of symptoms for SARS-CoV-2 infected individuals and after the first/second vaccination dose. Antibody profile assessment was done using whole-virus, spike-receptor binding domain (RBD) and nucleocapsid-specific ELISA kits along with neutralizing antibody kit. RESULTS: There was an overall 97.7 per cent seropositivity rate in vaccinated individuals, and a strong correlation (R(2)=0.8, P<0.001) between neutralizing and spike-RBD antibodies. Among individuals who received two standard doses of ChAdOx1 nCoV-19 vaccine, the spike antibody levels developed were of higher titre with a longer prime boost interval than in those with shorter intervals (P<0.01). Individuals vaccinated with two doses as well as only one dose post-SARS-CoV-2 infection had high neutralizing and spike-specific antibodies. INTERPRETATION & CONCLUSIONS: High neutralizing and spike-specific antibodies were developed in individuals vaccinated only with one dose of either vaccine post-SARS-CoV-2 infection. With the main priority being vaccinating majority of the population in our country, single-dose administration to such individuals would be a sensible way to make the most of the limited supplies. Furthermore, neutralizing antibody levels observed in COVID-19-naïve vaccinees imply the need for booster vaccination. Wolters Kluwer - Medknow 2022 2022-10-28 /pmc/articles/PMC9807196/ /pubmed/36124500 http://dx.doi.org/10.4103/ijmr.ijmr_3330_21 Text en Copyright: © 2022 Indian Journal of Medical Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Patil, Rucha Shanbhag, Sharda Shankarkumar, Aruna Madkaikar, Manisha Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals |
title | Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals |
title_full | Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals |
title_fullStr | Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals |
title_full_unstemmed | Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals |
title_short | Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals |
title_sort | antibody profile in post-vaccinated & sars-cov-2 infected individuals |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807196/ https://www.ncbi.nlm.nih.gov/pubmed/36124500 http://dx.doi.org/10.4103/ijmr.ijmr_3330_21 |
work_keys_str_mv | AT patilrucha antibodyprofileinpostvaccinatedsarscov2infectedindividuals AT shanbhagsharda antibodyprofileinpostvaccinatedsarscov2infectedindividuals AT shankarkumararuna antibodyprofileinpostvaccinatedsarscov2infectedindividuals AT madkaikarmanisha antibodyprofileinpostvaccinatedsarscov2infectedindividuals |